Healthcare Equipment and Supplies
Company Overview of Bayer HealthCare LLC
Bayer HealthCare LLC develops, manufactures, and markets healthcare and medical products. The company offers blood glucose monitoring systems, diabetes self-care software, and lancing devices; and YAZ, a low-dose oral contraceptive. It also provides diagnostic testing for urinalysis, DCA, immunology, blood gas, and hematology; molecular and clinical chemistry testing to assess and manage health in a myriad of disease states, including cardiovascular, kidney and infectious diseases, oncology, and virology; and Bayer Migraine Formula, an over-the-counter medication designed to relieve migraine pain and accompanying symptoms, including nausea, phonophobia, and photophobia. The company offers an...
100 Bayer Boulevard
PO Box 915
Whippany, NJ 07981-0915
Founded in 2002
Key Executives for Bayer HealthCare LLC
President and General Manager of Animal Health Division
President and General Manager, Animal Health Division, North America
President of Consumer Care Division
Sr. Vice President, Global Head, Product Supply -Biotech and Site Head
Bayer HealthCare Representative U.S.A.
Compensation as of Fiscal Year 2015.
Bayer HealthCare LLC Key Developments
U.S. Food & Drug Administration Approves Bayer HealthCare's Finacea(R) (azelaic acid) Foam 15% for Topical Treatment of the Inflammatory Papules and Pustules of Mild to Moderate Rosacea
Jul 31 15
Bayer HealthCare announced that the U.S. Food & Drug Administration (FDA) has approved Finacea® (azelaic acid) Foam, 15% for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. Papulopustular rosacea is a skin disease causing inflammatory lesions (papules and pustules) on the nose, cheeks, chin and forehead. Finacea® Foam was developed as part of a research and development collaboration between Foamix Pharmaceuticals Ltd. and Bayer HealthCare, utilizing Foamix's proprietary foam technology platform. According to a license agreement between the two companies, Foamix is entitled to royalties and certain milestone payments upon commercialization of Finacea® Foam.
Bayer HealthCare and Johns Hopkins University Collaborate to Develop New Ophthalmic Therapies
Jun 16 15
Bayer HealthCare and The Johns Hopkins University in Baltimore have entered into a five-year collaboration agreement to jointly develop new ophthalmic therapies targeting retinal diseases. The partners will jointly work on the discovery and development of innovative drugs for the treatment of serious back-of-the-eye diseases that affect many people worldwide, including age-related macular degeneration (AMD), diabetic macular edema (DME), geographic atrophy, Stargardt's disease, and retinal vein occlusion (RVO). The goal of the strategic research alliance is to accelerate the translation of innovative approaches from the laboratory to the clinic, ultimately offering patients new treatment options for several retinal diseases. Under the agreement, Bayer and the Wilmer Eye Institute of Johns Hopkins will jointly conduct research activities evaluating new targets and disease mechanisms, drug delivery technologies, and biomarkers for back-of-the-eye diseases with high unmet medical need. Both parties will contribute personnel and infrastructure to address important scientific questions. Bayer will have an option for the exclusive use of the collaboration results. Financial terms of the agreement were not disclosed.
Acura Pharmaceuticals, Inc. and Bayer Healthcare LLC Enter into License and Development Agreement
Jun 16 15
On June 15, 2015, Acura Pharmaceuticals Inc. and Bayer Healthcare LLC entered into a license and development agreement made as of June 5, 2015 to: (i) provide Bayer with a worldwide license to Acura’s Impede® technology for use in an undisclosed methamphetamine resistant pseudoephedrine-containing product and (ii) jointly develop the Product utilizing Impede® technology for the U.S. market. The agreement also grants Bayer first right to negotiate a license to the Impede® technology for certain other products. The term of the agreement with respect to each country expires when royalties are no longer payable with respect to such country. After expiration of the term Bayer retains a license to sell the product on a royalty free basis. Either party may terminate the agreement in its entirety if the other party materially breaches the agreement, subject to an applicable cure period, or in the event the other party makes an assignment for the benefit of creditors, files a petition in bankruptcy or otherwise seeks relief under applicable bankruptcy laws. Bayer may terminate the agreement immediately prior to completion of development obligations or at any time upon six months prior written notice thereafter. The company may terminate the agreement with respect to the U.S. if Bayer ceases or suspends development or commercialization of the product for a certain period of time.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|